Printed from the IBC Life Sciences Web site on March 11, 2014 1:11 AM ET.
Page location: http://www.ibclifesciences.com/AsiaTIDES/overview.xml
February 25 - February 27,--> 2014 · Tokyo, Japan
ATTRIBUTES OF A GOOD PEPTIDE
Andrew A. Young, MD, Ph.D.
Vice President, Head of Enteroendocrine Biology, GlaxoSmithKline, USA
PSEUDO-NATURAL PRODUCT THERAPEUTICS
Hiroaki Suga, Ph.D.
Professor, Chemical and Biotechnology Lab, University of Tokyo, Japan
ANTISENSE: WITHIN SIGHT OF THE FINISH LINE
Henrik Ørum, Ph.D.
Chief Scientific Officer, Santaris Pharma A/S, Denmark
DAVUNETIDE - LESSONS LEARNED
Bruce Morimoto, Ph.D.
Executive Director, Applied Translational Medicine, Celerion, USA
UPDATE ON NA-1 PEPTIDE
Dave Garman, Ph.D.
Technology Officer, NoNO Inc., Canada
UPDATE ON LPN-MEDIATED MESSENGER RNA DELIVERY
Ian MacLachlan, Ph.D.
Executive Vice President and Chief Technology Officer, Tekmira Pharmaceuticals Corp., Canada
The conference will be conducted in English without translation.
Join our priority contact list and receive the latest event news.
AsiaTIDES 2013 Presentations Now Available!
» Learn More
IBC Life Sciences' 6th Annual AsiaTIDES conference continues to provide the evolving oligonucleotide and peptide therapeutic fields in Japan and throughout Asia with a forum to share the latest groundbreaking science and form successful business collaborations.
Access up-to-date development reports from Aileron Therapeutics Inc., AM Biotechnologies, Bicycle Therapeutics, BIONEER, Immunovaccine Inc., InDex, Isis, miRagen, Nexigen GmbH, Noxxon, OncoTherapy, RXi Pharmaceuticals, Santaris Pharma, and more.
Hear regulatory and safety assessment considerations for peptides and oligonucleotides from two former U.S. Food and Drug Administration Officials, and a case study on whether the ICH-S6(R1) guideline is applicable for oligonucleotides.
Learn manufacturing capabilities from major oligonucleotide and peptide CMOs and understand what is happening on the academic research front.
Plus! Gain immediately applicable knowledge from three tutorials for 2014: Manufacturing of Oligonucleotide Drugs, The Challenge of Oligonucleotide In Vivo Delivery; and Evolution of a CMC Section Throughout a Peptide Product Life Cycle.
Access the latest updates on science, business developments, and regulatory challenges in just three days. Don't miss this opportunity to network with leaders around the world and reinforce your development portfolio.
"The best RNAi Therapeutics-related conference in Asia! A great place to network, connect the East and West, and catch up with the latest cutting-edge science." - Dirk Haussecker, D. Phil, Assistant Professor, Medical Biotechnology, Dongguk University, South Korea